Every material Form 8-K Trulieve Cannabis Corp. has filed with the SEC since August 07, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Trulieve reported third-quarter 2026 revenue of $230 million, down 20% from $288 million a year earlier, and net income attributable to common shareholders of $0.9 million, compared with a loss of $26.8 million in the same quarter of 2025. The company said Q3 2026 includes only its medical operations, while prior periods include Harvest's mixed medical and adult-use results, so the comparison is not like-for-like. Nine-month results show a net loss of $402.7 million, driven mainly by a $403.3 million loss on the June 2026 deconsolidation of Harvest, and the filing gives no financial guidance.
Revenue of $230 million, down 20% from $288 million; gross margin of 64% versus 59% a year earlier.
Net income attributable to common shareholders of $0.9 million, or $0.00 per diluted share, versus a loss of $26.8 million, or $0.14 per share, in Q3 2025.
Adjusted EBITDA of $89 million (39% of revenue), down from $103 million; cash and cash equivalents of $326.7 million at September 30, 2026.
Nine-month net loss of $402.7 million, including a $403.3 million loss on deconsolidation of Harvest operations recorded in the period.
Trulieve Cannabis Corp. completed its domestication from British Columbia to Delaware, and its British Columbia shares were automatically exchanged one-for-one into Delaware common stock. Shareholder rights are now governed by a new Delaware certificate of incorporation, bylaws and the Delaware General Corporation Law, which differ in certain respects from the prior British Columbia documents and law.
Each BC Subordinate Voting Share was exchanged for one Class A subordinate voting common share, and each BC Multiple Voting Share for one Class B multiple voting common share, par value $0.0001.
Outstanding stock options, RSUs and PSUs were converted into equivalent awards under the Third Amended and Restated Trulieve Cannabis Corp. 2021 Omnibus Incentive Plan.
The company adopted a new Certificate of Incorporation and Bylaws, and entered into or will enter into indemnification agreements with its executive officers and directors.
The share issuance relied on the Section 3(a)(10) exemption from Securities Act registration.
Trulieve reported second quarter 2026 revenue of $271 million, down 10% from $302 million a year earlier, and a GAAP net loss attributable to common shareholders of $406 million, or $2.10 per share. The loss was driven mainly by a $403.3 million loss on the deconsolidation of Harvest, completed June 3, 2026, while adjusted net income of $20 million ($0.11 per share) compared with an adjusted net loss of $8 million a year earlier.
Revenue of $271 million, down 10% from $302 million in Q2 2025 and down 6% from $287 million in Q1 2026
Net loss attributable to common shareholders of $406 million ($2.10 per share), including a $403.3 million loss on the Harvest deconsolidation
Adjusted net income of $20 million ($0.11 per share) versus an adjusted net loss of $8 million in Q2 2025; adjusted EBITDA of $98 million, down 11% from $111 million
Cash and cash equivalents of $325.4 million at June 30, 2026
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Trulieve Cannabis Corp. filing is on SEC EDGAR ↗. 8-K briefs of other companies →